A water-soluble green coffee bean extract (GCE) has been shown to be effective against hypertension in both spontaneously hypertensive rats and humans. This multicenter, randomized, double-blind, placebocontrolled, parallel group study evaluated the dose-response relationship of GCE in 117 male volunteers with mild hypertension. Subjects were randomized into four groups: a placebo and three drug groups that 
Introduction
Hypertension is a primary risk factor for stroke, heart disease, and renal failure, and one of the most critical issues for human health (1−5) . Hypertension is also a lifestyle-related disease, and modifications in lifestyle are effective for its prevention: i.e., engaging in moderate physical activity; maintaining normal body weight for adults; limiting alcohol consumption; reducing sodium intake; maintaining adequate intake of potassium; and consuming a diet rich in fruits, vegetables, and low-fat dairy products with a reduced content of saturated and total fat (4) . Patients with mild hypertension (systolic blood pressure [SBP] /diastolic blood pressure [DBP] , 140− 159/90−99 mmHg) with no risk factors and with presence of risk factors beside diabetes are classified into low-risk and medium-risk, respectively. In low-risk and medium-risk hypertensive patients, lifestyle changes should be the first therapeutic measure, but if the blood pressure does not decline to an SBP of below 140 mmHg and DBP of below 90 mmHg, then antihypertensive drug treatment should be started (5) .
As an alternative to drug therapy, it is desirable to use foods or food components for the prevention and/or treatment of hypertension and thereby avoid the adverse effects of organically synthesized drugs as well as the high cost of drug therapy (6) . Many investigators report that antioxidant vitamins (7−10) and supplements (11) , peptides from milk (6, 12) or fish protein (13) , polyunsaturated fatty acids (14) , and many food components (15−24) reduce blood pressure in humans and animals. The application of foods or food components is thus expected to be effective as part of the primary therapy for patients with mild hypertension.
A water-soluble green coffee bean extract (GCE) has been shown to reduce blood pressure in spontaneously hypertensive rats (25) and humans (26) . The GCE used in these reports was a hot-water extract of green coffee beans that contained chlorogenic acid as a major ingredient. Orally administered chlorogenic acid is metabolized to ferulic acid in the liver and/or kidneys (27) . Ferulic acid, which is a metabolite of GCE containing chlorogenic acid, decreases blood pressure (25) and improves vasoreactivity (28) .
GCE may be considered a novel antihypertensive food component. We conducted a multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy of antihypertensive treatment with an oral GCE that contained high doses of chlorogenic acid for patients with mild hypertension.
Methods

Study Design
The current study was a randomized, double-blind, placebocontrolled, parallel group, dose-response study conducted for 28 days at 8 centers in Japan. The study was conducted in compliance with the Declaration of Helsinki (1964) and its revised version (2002). The protocol was reviewed and approved by the Clinical Trial Ethics Committee of Isogo Central and Neurosurgical Hospital (Yokohama, Japan) before the start of the study. The nature of the study, the proposal for the study design, and the potential risks of participation in the study were fully explained to each volunteer, and written consent was obtained.
Subjects
Healthy male volunteers, aged 30 to 50 years, with mild hypertension (SBP between 140 and 159 mmHg, and/or DBP between 90 and 99 mmHg) (5) were included in this study. Subjects were excluded if they were heavy smokers (> 15 cigarettes/day) or hardened drinkers (> 30 g alcohol/day), if they had received antihypertensive therapy, or if they exhibited abnormal liver function (aspartate aminotransferase > 100 IU/l and/or alanine aminotransferase > 100 IU/l) or abnormal renal function (blood urea nitrogen > 23 mg/dl and/or serum creatinine > 1.3 mg/dl).
Test Diet
The test diet was a soy sauce-flavored instant cup soup containing GCE, which was a hot-water extract of dried, green unroasted coffee beans (flavor folder RC; T. Hasegawa Co., Ltd., Tokyo, Japan). The components of GCE are shown in Table 1 . In human clinical trials, GCE was reported to have no adverse effects on hematological parameters and/or blood chemistry (26, 28) .
The test diet was eaten at breakfast and consisted of one 10-g pack of soup base ( Table 2) and one of three different types of freeze-dried food⎯"wakame" seaweed, tofu soybean curd, or deep-fried tofu soybean curd⎯stirred in a cup with 180 ml of hot water ( Table 3 ). The soup base contained 0 mg (placebo), 46 mg, 93 mg, or 185 mg of GCE in 10 g of lowsodium soy sauce ( Table 2 ). The amounts of chlorogenic acid included in these different quantities of GCE were 0 mg, 25 mg, 50 mg, and 100 mg, respectively.
The addition of GCE caused no changes in the color or the taste of the soy soup, and no taste difference was detected between the test diets and the placebo diets. The test diets⎯i.e., the soup bases and ingredients⎯included 1.21− 1.25 g of salt.
Measurement of Blood Pressure
Blood pressure and pulse were measured 14 days before the trial, at baseline (0 days), and at 14 and 28 days after the start of the test period under the morning fasting condition at trough (24±3 h after the last test-diet ingestion). Three measurements were taken in the right arm using automated sphygmomanometers (Table 4 ) and an appropriate-sized cuff after at least 10 min of rest in the seated position. The median of three measurements was taken as the measured value.
Protocol
Based on the blood pressure measured 14 days before the trial, subjects were randomly assigned to four groups (a placebo or a 46, 93, or 185 mg group). Subjects were also randomized to an approximately equal testing group distribution in each center. At baseline (0 day) and 28 days, the body weights were measured, and fasting blood samples were collected after the blood pressure measurement and subjected to hematological evaluation (white blood cells, red blood cells, platelets, hematocrit, and hemoglobin) and blood chemistry tests (aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase, alkaline phosphatase, lactate dehydrogenase, blood urea nitrogen, serum creatinine, uric acid, total protein, albumin, total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol) at each center. Adverse events (Table 5) were checked by physicians' interview using a case-report form at baseline (0 day), 14 days, and 28 days.
Each subject provided 3 days of food records prior to each visit. The food records were analyzed by a registered dietitian using the Japanese food composition database (Japan Science and Technology Agency, http://food.tokyo.jst.go.jp/) to determine average intakes of energy and salt. Subjects were asked not to change their dietary habits during the study, particularly in regard to their consumption of fat, salt, vegetables, and fruits.
Statistical Analysis
The characteristics of groups at baseline were compared by one-way analysis of variance (ANOVA). The changes in trough blood pressures, pulse, body weight, energy intake, and salt intake were analyzed using one-way repeated measures ANOVA for comparisons with the baseline and twoway repeated measures ANOVA for comparisons of the differences among the four test groups. Values were expressed 
Results
One hundred twenty-six applicants were recruited for the study, but 9 were excluded based on the exclusion criteria at recruitment. Thus a total of 117 subjects were randomized, and all completed the study. At baseline in the study, there were no significant differences among the four groups in blood pressure, pulse, age, weight, body mass index (BMI), blood components, dietary energy intake, or dietary salt intake (Table 6 ). Subjects had a mean compliance of 99.85% as estimated by food records. Three subjects failed to ingest the test diet once, and one subject failed to ingest the test diet twice; thus 113 subjects ingested 100% of the doses of the test diet. Trough SBPs of the placebo group and the testing groups were significantly reduced from baseline (p= 0.018, p= 0.0002, p< 0.0001, and p< 0.0001 for the placebo group, the 46 mg group, the 93 mg group, and the 185 mg group, respectively), and the reductions in the trough SBPs of the placebo group, the 46 mg group, the 93 mg group, and the 185 mg group after 28 days were -1.3±3.0 mmHg, -3.2±4.6 mmHg, -4.7±4.5 mmHg and -5.6±4.2 mmHg, respectively. There were significant differences between the placebo group and both the 93 mg group (p< 0.05) and the 185 mg group (p< 0.01) (Fig. 1) . The trough DBP of the placebo group was not reduced significantly (p= 0.296), whereas those of the testing groups showed significant decreases (p< 0.0001 for (Fig. 1) . A significant quadratic trend in the trough BP reduction was evident among GCE doses (SBP: r= -0.374, p= 0.0002; DBP: r= -0.351, p= 0.0006) (Fig. 2) .
No significant body weight, energy intake, or pulse changes from baseline were observed in the three test groups or placebo group or among the four test groups ( Table 7) . The daily salt intake increased significantly from baseline (p< 0.0001) because the test diets included salts. However, no significant differences in daily salt intake among the four test groups were observed (p= 0.395; Table 7) .
No adverse effects originating in the test or placebo diets were observed in the clinical examination, physical examination, or medical examination/history taking ( Table 7) .
Discussion
In the present study, we demonstrated for the first time that GCE reduced blood pressure in patients with mild hypertension in a dose-related manner. The main component of GCE is chlorogenic acid (Table 1) . Oral administration of chloro- genic acid, as well as the oral administration of GCE, has been shown to reduce blood pressure in spontaneously hypertensive rats (25) . About one-third of the ingested chlorogenic acid enters into the blood circulation via absorption from the small intestine in humans (29) . The absorbed chlorogenic acids are metabolized to caffeic acid, quinic acid, and ferulic acid, and traces of chlorogenic acid are not metabolized but excreted in urine (27) . A metabolite of chlorogenic acid, ferulic acid, reduces blood pressure (25) , acts on NO derived from the vascular endothelium (30) , and improves vasoreactivity by acting directly on the blood vessels (28) . Blood pressure is related to oxidant stress (31−33) . Oxidant stress is increased, and antioxidant mechanism activities are reduced in hypertensive patients (34) . Antioxidant vitamins (i.e., ascorbic acid and tocopherol) reduce blood pressure (8− 10) and improve blood vessel endothelial dysfunction in patients with hypertension (35, 36) . Ascorbic acid scavenges oxygen free radicals and improves endothelium-dependent vasodilatation by restoring nitric oxide activity in essential hypertension (35, 36) . Chlorogenic acid, caffeic acid, and ferulic acid have antioxidant potencies that are the same as or a little weaker than that of ascorbic acid (37−42) . The antioxidant property of chlorogenic acid, which is the main component of GCE and of the metabolites of chlorogenic acid, might improve endothelial dysfunction and reduce blood pressure. Further studies are necessary to investigate the mechanism of the antihypertensive effect of GCE and/or chlorogenic acid.
Many studies have reported a correlation between blood pressure and salt intake (43−48) . In this study, although all the test diets included salt, none of them was found to increase blood pressure.
This study demonstrated that the daily intake of 93 mg of GCE (50 mg of chlorogenic acid) reduced SBP and DBP by 4.7 mmHg and 3.2 mmHg, respectively. A reduction of 5 mmHg in SBP reduces stroke and coronary heart disease mortality by 14% and 9%, respectively (4). A reduction of 2 mmHg of DBP could be associated with 14% fewer strokes and 8% less coronary heart disease (49). Ochiai et al. reported that ingestion of a GCE drink containing 140 mg of chlorogenic acid for 4 months had no adverse or hypotensive effects on normal blood pressure subjects (28) . In our study, no adverse effects from GCE were observed. Our results indicate that daily intake of GCE reduces blood pressure in hypertensive subjects and may help to prevent stroke and coronary heart disease.
